icosapent ethyl / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 26 Diseases   6 Trials   6 Trials   4342 News 


«12...2829303132333435363738...5051»
  • ||||||||||  Vascepa (icosapent ethyl) / Amarin, HLS Therap
    Needs vascepa. (Twitter) -  Apr 10, 2020   
  • ||||||||||  Vascepa (icosapent ethyl) / Amarin, HLS Therap
    Review, Journal:  Cardiovascular, electrophysiologic, and hematologic effects of omega-3 fatty acids beyond reducing hypertriglyceridemia: as it pertains to the recently published REDUCE-IT trial. (Pubmed Central) -  Mar 31, 2020   
    The recently published REDUCE-IT trial demonstrated a statistically significant absolute risk reduction of 4.8% in its primary endpoint (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina) with the use of icosapent ethyl, which is a highly purified eicosapentaenoic acid (EPA) ethyl ester...Moreover, the use of EPA was not without risk, as the incidence of atrial fibrillation was increased along with a trend towards increased bleeding risk. Thus, our aim is to help explain the function of purified EPA ethyl ester, especially at the molecular level, which will ultimately lead to a better understanding of their clinically observable effects.
  • ||||||||||  icosapent ethyl / Generic mfg.
    Journal:  Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT. (Pubmed Central) -  Mar 29, 2020   
    P3
    Thus, our aim is to help explain the function of purified EPA ethyl ester, especially at the molecular level, which will ultimately lead to a better understanding of their clinically observable effects. Among statin-treated patients with elevated triglycerides and cardiovascular disease or diabetes, multiple statistical models demonstrate that icosapent ethyl substantially reduces the burden of first, subsequent, and total ischemic events.
  • ||||||||||  icosapent ethyl / Generic mfg.
    Journal:  Risk of Total Events With Icosapent Ethyl: Can We Reduce It? (Pubmed Central) -  Mar 26, 2020   
    Among statin-treated patients with elevated triglycerides and cardiovascular disease or diabetes, multiple statistical models demonstrate that icosapent ethyl substantially reduces the burden of first, subsequent, and total ischemic events. No abstract available
  • ||||||||||  Vascepa (icosapent ethyl) / Amarin, HLS Therap
    Biomarker, Review, Journal:  Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options. (Pubmed Central) -  Mar 26, 2020   
    Finally, in regard to lipoprotein(a)-which is a strong risk factor for ASCVD-there are exciting developments in the therapeutic pipeline which reduce circulating lipoprotein(a) levels by nearly 90%. The management of dyslipidemias continues to be an exciting field with several ongoing cardiovascular outcomes trials, improvement in risk prediction models, and new therapeutic agents in the pipeline that will further mitigate residual cardiovascular risk in both primary and secondary prevention patients.